Context  Adequate vitamin D status for optimum bone health has received increased recognition in recent years; however, the ideal intake is not known. Serum 25-hydroxyvitamin D is the generally accepted indicator of vitamin D status, but no universal reference level has been reached.

Objective  To investigate the relative importance of high calcium intake and serum 25-hydroxyvitamin D for calcium homeostasis, as determined by serum intact parathyroid hormone (PTH).

Design, Setting, and Participants  Cross-sectional study of 2310 healthy Icelandic adults who were divided equally into 3 age groups (30-45 years, 50-65 years, or 70-85 years) and recruited from February 2001 to January 2003. They were administered a semi-quantitative food frequency questionnaire, which assessed vitamin D and calcium intake. Participants were further divided into groups according to calcium intake (<800 mg/d, 800-1200 mg/d, and >1200 mg/d) and serum 25-hydroxyvitamin D level (<10 ng/mL, 10-18 ng/mL, and >18 ng/mL).

Main Outcome Measure  Serum intact PTH as determined by calcium intake and vitamin D.

Results  A total of 944 healthy participants completed all parts of the study. After adjusting for relevant factors, serum PTH was lowest in the group with a serum 25-hydroxyvitamin D level of more than 18 ng/mL but highest in the group with a serum 25-hydroxyvitamin D level of less than 10 ng/mL. At the low serum 25-hydroxyvitamin D level (<10 ng/mL), calcium intake of less than 800 mg/d vs more than 1200 mg/d was significantly associated with higher serum PTH (P=.04); and at a calcium intake of more than 1200 mg/d, there was a significant difference between the lowest and highest vitamin D groups (P=.04).

Conclusions  As long as vitamin D status is ensured, calcium intake levels of more than 800 mg/d may be unnecessary for maintaining calcium metabolism. Vitamin D supplements are necessary for adequate vitamin D status in northern climates.

JAMA. 2005;294:2336-2341  www.jama.com

See also Patient Page.
serum PTH concentration, and reported threshold levels have varied greatly from 8 to 44 ng/dL.7,8 This wide range may be in part due to different methods for measuring both serum PTH and 25-hydroxyvitamin D and defining baseline levels,9 and possibly also due to different calcium intakes in study populations since serum calcium regulates PTH release.10 The interrelationship between calcium intake and vitamin D requirements has not been addressed adequately in the past.

The goal of our study was to investigate the relative importance of high calcium intake and serum 25-hydroxyvitamin D for calcium homeostasis in healthy adults, as determined by serum intact PTH.

**METHODS**

**Participants**

A total of 2310 men and women were divided equally between 3 age groups (30-45 years, 50-65 years, and 70-85 years), identified by a stratified, random selection process from the computerized population register of Reykjavik, the capital of Iceland, and invited to participate in our cross-sectional study on bone health. In the preparatory phase of the study, we determined the sample size to have 80% power to detect a 20% difference in key bone factors between groups of 100 patients, at the \( \alpha = 0.05 \) significance level, assuming an SD of half the mean for the factor. With a 65% to 70% expected participation rate and after exclusions for various conditions, we predicted that the total of 2310 participants would be needed for invitation to the study. Women outnumbered men in the sample (n = 1370 and n = 940, respectively) because a greater proportion of women were expected to be excluded from the study due to hormonal use. The recruitment period was from February 2001 to January 2003, with an equal number of participants from each age group recruited monthly throughout the 2-year period to account for seasonal effects. The participants answered a detailed questionnaire on health-related issues, height and weight were measured, and body mass index (BMI) was calculated as weight in kilograms divided by the square of height in meters. The Icelandic Medical Ethics Committee approved the study, and all participants provided a written consent form.

**Biochemistry**

After overnight fasting, blood was drawn between 8 and 10 AM, and serum 25-hydroxyvitamin D levels were measured using radioimmunoassay (DiaSorin, Stillwater, Minn). Interassay variations were 6.9% and 8.5% for serum 25-hydroxyvitamin D levels of 14.8 and 50.8 ng/dL, respectively. Intact serum PTH was measured using an immunoassay (ElectroChemiluminescence Immuno Assay, Elecsys 2010, Roche Diagnostics, Tenzberg, Germany). Interassay variation was 2.9% for a serum PTH level of 68.0 pg/mL. Serum cystatin C was measured by an immunoturbidimetric assay (DakoCytomation, Copenhagen, Denmark), and serum ionized calcium was measured by an ion-specific electrode (ABL 700, Radiometer, Copenhagen, Denmark); coefficient of variation was 1.0% and 2.2% for serum ionized calcium levels of 4.12 and 6.40 mg/dL (1.03 and 1.60 mmol/L), respectively.

**Data Analysis**

We used analysis of variance (ANOVA) to compare the 3 age groups with respect to continuous variables, applying the Bonferroni method to control for multiple comparisons. Two groups based on supplement use were compared using analysis of covariance (ANCOVA). Participants were divided into groups according to calcium intake (<800 mg/d, 800-1200 mg/d, and >1200 mg/d), and according to serum 25-hydroxyvitamin D level (<10 ng/mL, 10-18 ng/mL, and >18 ng/mL). Our main analysis by ANCOVA was to study the relationship between serum intact PTH levels and both calcium intake and serum 25-hydroxyvitamin D levels, with and without the interaction between calcium intake and vitamin D status in the model. Calcium intake groups and 25-hydroxyvitamin D groups were fixed factors, and variables known to be associated with PTH levels were entered as covariates, which included the continuous variables age, BMI, and cystatin C (as a measure of kidney function, independent of muscle mass and sex), and the categorical variables sex (male/female) and smoking (yes/no). We also tested for interaction between vitamin D status or calcium intake and the categorical variables smoking and sex, but these were not significant. For subsequent subgroup comparisons, we used Bonferroni adjustment for multiple comparisons. Groups were compared with regard to serum ionized calcium using ANOVA and the Bonferroni adjustment. Data are presented as mean (SD), unless otherwise noted. Statistical analysis was performed by using SPSS version 11.5 (SPSS Inc, Chicago, Ill). \( P<.05 \) was considered statistically significant.

**RESULTS**

A total of 1630 (70.7%) of 2310 individuals from the initial invited sample participated in the study; all were white. For our analysis, 625 participants were excluded because of diseases or medications thought to affect calcium metabolism, which included hormone therapy (n = 304), thiazide diuretics (n = 203), prednisolone (n = 35), bisphosphonates (n = 40), tamoxifen...
PARATHYROID HORMONE LEVELS, VITAMIN D, AND CALCIUM INTAKE

Mean Intake and Serum Values by Age Group

<table>
<thead>
<tr>
<th>Parameter</th>
<th>30-45 (n = 358)</th>
<th>50-65 (n = 314)</th>
<th>70-85 (n = 245)</th>
<th>P Value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vitamin D intake, IU/d</td>
<td>388 (360)</td>
<td>552 (404)</td>
<td>664 (416)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Calcium intake, mg/d</td>
<td>1175 (537)</td>
<td>1239 (552)</td>
<td>1308 (529)</td>
<td>.05</td>
</tr>
<tr>
<td>Serum 25-hydroxyvitamin D, ng/mL</td>
<td>17.1 (7.9)</td>
<td>18.3 (7.9)</td>
<td>20.7 (7.4)</td>
<td>.001</td>
</tr>
<tr>
<td>Serum parathyroid hormone, pg/mL</td>
<td>35.8 (16.0)</td>
<td>37.7 (15.4)</td>
<td>41.7 (17.0)</td>
<td>.01</td>
</tr>
<tr>
<td>Serum cystatin C, mg/L</td>
<td>0.9 (0.2)</td>
<td>1.0 (0.2)</td>
<td>1.2 (0.3)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Serum ionized calcium, mg/dL</td>
<td>4.92 (0.14)</td>
<td>4.95 (0.15)</td>
<td>4.97 (0.15)</td>
<td>.05</td>
</tr>
</tbody>
</table>

St conversions: To convert serum 25-hydroxyvitamin D to nmol/L, multiply by 2.496; serum ionized calcium to mmol/L, multiply by 0.25.

*Calculated by analysis of variance with Bonferroni adjustment.

**Table.** Mean Intake and Serum Values by Age Group

**Figure 1.** Seasonal Variation in Serum 25-Hydroxyvitamin D by Supplementation

<table>
<thead>
<tr>
<th>Month</th>
<th>Yes (n = 562)</th>
<th>No (n = 382)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Feb-Mar</td>
<td>34.2 (9.6)</td>
<td>30.9 (9.1)</td>
</tr>
<tr>
<td>Apr-May</td>
<td>35.8 (9.1)</td>
<td>33.0 (8.6)</td>
</tr>
<tr>
<td>Jun-Jul</td>
<td>40.2 (11.0)</td>
<td>36.2 (10.2)</td>
</tr>
<tr>
<td>Aug-Sep</td>
<td>42.3 (12.4)</td>
<td>38.4 (11.6)</td>
</tr>
<tr>
<td>Oct-Nov</td>
<td>39.4 (11.0)</td>
<td>35.5 (10.4)</td>
</tr>
<tr>
<td>Dec-Jan</td>
<td>36.8 (9.8)</td>
<td>32.9 (9.3)</td>
</tr>
</tbody>
</table>

Data are presented as mean (SD). To convert serum 25-hydroxyvitamin D to ng/mL, divide by 2.496.

(n = 18), phenytoin (n = 5), major gastrointestinal surgery (n = 28), and primary hyperparathyroidism (n = 21); some participants were taking more than 1 medication. In addition, 61 participants were excluded because they failed to complete the dietary questionnaire. After all exclusions, 944 healthy participants remained who had completed all parts of the study (491 women; mean [SD] age, 53.7 [16.1] years; and 453 men; mean [SD] age, 57.9 [14.3] years).

Mean (SD) values for vitamin D and calcium intake, serum 25-hydroxyvitamin D, serum PTH, serum cystatin C, and serum ionized calcium in the 3 age groups are presented in the **Table.** All parameters were significantly higher in the oldest age group (70-85 years) compared with the youngest age group (30-45 years). Although mean intake of calcium and vitamin D were above recommended levels in all age groups, there was great variation in individual intake, especially for vitamin D.

**Figure 1** presents mean serum 25-hydroxyvitamin D at 2-month intervals throughout the year for 2 groups (those participants taking vitamin D supplements or cod-liver oil regularly [n = 562] and those not taking supplements [n = 382]). Mean (SD) vitamin D intake levels were significantly higher in the group taking supplements compared with nonsupplement users (728 [372] vs 208 [200] IU/d; P < .001). ANOVA with no covariates; 1 μg corresponding to 40 IU of vitamin D, and was reflected in higher serum 25-hydroxyvitamin D levels, especially during the winter months, where mean (SD) levels decreased to 11.5 (5.5) ng/mL from February to March in those individuals not taking supplements but remained at 18.7 (8.1) ng/mL in the group taking supplements. Peak values during summer months, June to July, differed less between the groups but stayed nevertheless higher in supplement users at 22.4 (6.9) ng/mL compared with 18.3 (9.3) ng/mL in nonsupplement users. The difference in serum 25-hydroxyvitamin D levels between supplement and nonsupplement users was statistically significant (P < .001, ANCOVA controlling for season). In addition, serum PTH levels were significantly lower in supplement users compared with nonsupplement users (adjusted means, 36.9 vs 39.5 pg/mL; P = .02, ANCOVA controlling for age, sex, smoking, BMI, and cystatin C). As expected, we found an inverse relationship between serum 25-hydroxyvitamin D and serum PTH levels; however, at serum 25-hydroxyvitamin D levels of more than 18 ng/mL, this relationship became statistically nonsignificant and only minor decrements in serum PTH levels were observed with serum 25-hydroxyvitamin D levels of more than 18 ng/mL. We therefore used a serum 25-hydroxyvitamin D level of 18 ng/mL to define vitamin D sufficiency.

In our main analysis, which examined factors in the model without the interaction term, vitamin D status was significantly associated with serum PTH (P < .001), whereas the calcium intake group was not (P = .28). In the model with the interaction term, both vitamin D status (P < .001), calcium intake group (P = .02), and the interaction between the 2 (P = .01) were significantly associated with serum PTH levels, as were all the covariates (all P ≤ .001). **Figure 2** shows the adjusted means from the latter model for serum PTH according to serum 25-hydroxyvitamin D in the 3 calcium intake groups. The lowest serum PTH levels were observed in the group with a serum 25-hydroxyvitamin D level of more than 18 ng/mL, with a small difference between the calcium intake groups, whereas the highest serum PTH was observed in the group with a serum 25-hydroxyvitamin D level of less than 10 ng/mL. In this group, serum PTH levels were highest in the low calcium group. Thus, Figure 2 and the overall statistical model indicated a strong association between vitamin D status and serum PTH.
whereas the effect of calcium intake may be most important in the low vitamin D status group.

Further analysis of differences between subgroups was therefore limited to comparing the lower 2 calcium intake groups with the highest one within the lowest vitamin D status group, and the lower vitamin D status groups to the highest one within the highest calcium intake group. This was performed by using ANCOVA, adjusting for covariates and applying the Bonferroni method for multiple comparisons (total of 4 comparisons). At the low serum 25-hydroxyvitamin D level, there was a significant difference in serum PTH according to calcium intake. Serum PTH was significantly higher when the calcium intake level was less than 800 mg/d compared with more than 1200 mg/d (P < .04, ANCOVA with Bonferroni correction), whereas the serum PTH levels of those individuals with a calcium intake of between 800 and 1200 mg/d were not significantly different from those individuals with a level of more than 1200 mg/d. Within the highest calcium intake group, there was a significant difference between the lowest and the highest vitamin D groups (P < .04, ANCOVA with Bonferroni correction), whereas the difference between the middle and the highest groups was nonsignificant.

Mean serum ionized calcium was slightly but significantly lower in the group with the lowest serum 25-hydroxyvitamin D level compared with the highest group (4.908 vs 4.964 mg/dL, 1227 vs 1241 mmol/L; P < .01, ANOVA with Bonferroni adjustment for 6 comparisons). There was no significant difference in ionized calcium between the calcium intake groups, and the interaction between calcium intake and vitamin D sufficiency groups was not statistically significant. The lowest ionized calcium level was observed in the group with a serum 25-hydroxyvitamin D level of less than 10 ng/mL and calcium intake of less than 800 mg/d, or 4.72 mg/dL (1.18 mmol/L).

When all analyses above were performed on all 1630 participating individuals, including those excluded because of medications or diseases, similar results were obtained.

**COMMENT**

Our study examined calcium intake and serum levels of 25-hydroxyvitamin D with respect to optimal serum PTH. Parathyroid hormone is a major hormone maintaining normal serum concentrations of calcium and phosphate and is itself regulated through levels of calcitriol and serum calcium. An insufficiency of vitamin D or calcium is generally associated with an increase in PTH, but to our knowledge the relative importance of each nutrient to this process has not been addressed previously.

Our study was performed in a healthy adult population, living at a northern latitude (64° North), where sufficient sunshine for cholecalciferol biosynthesis is limited to the spring to autumn months. The study by Webb et al demonstrated the effect of latitude on vitamin D biosynthesis, with no synthesis occurring due to sun exposure from December to February in Boston, Mass (42° North) and from November to March in Edmonton, Alberta, Canada (52° North). Our results point to a situation close to that in Edmonton, with serum 25-hydroxyvitamin D reaching its lowest values during the 2-month period from February to March. However, supplement use is common in this population, with 60% of our sample taking either cod-liver oil or vitamin D supplements regularly. The traditional use of cod-liver oil, which contains a high concentration of vitamin D, is especially common in older age groups in Iceland, accounting for higher mean intake levels in that age group.

Calcium intake is also relatively high in our sample, especially in older people, reflecting the common dietary pattern in Iceland and traditional use of milk products as verified in a recent national nutrition survey. In spite of the high mean intake levels, there is considerable variation in both nutrients, allowing for the division of the sample into 3 groups of calcium intake (<800 mg/d, 800-1200 mg/d, and >1200 mg/d), as well as 3 groups of serum 25-hydroxyvitamin D (<10 ng/mL, 10-18 ng/mL, and >18 ng/mL).

The significance of our study was demonstrated by the strong negative association between sufficient serum levels of 25-hydroxyvitamin D and PTH, with calcium intake varying from less than 800 mg/d to more than 1200 mg/d. Our results suggest that vitamin D sufficiency can ensure ideal serum PTH values even when the calcium intake level is less than 800 mg/d, while high calcium intake (>1200 mg/d) is not sufficient to maintain ideal serum PTH, as long as vitamin D status is insufficient. This is further reflected in ionized calcium levels that were dependent on serum 25-hydroxyvitamin D levels but not on calcium intake. High calcium intake does, however, ameliorate the increase in serum PTH that accompanies vitamin D insufficiency and does permit somewhat lower serum 25-hydroxyvitamin D levels for maintaining ideal serum PTH.

Although a cross-sectional study such as our study is not sufficient to demonstrate causality, the association between vitamin D status, calcium intake, and the interaction between these 2 with serum PTH levels is a strong in-
PARATHYROID HORMONE LEVELS, VITAMIN D, AND CALCIUM INTAKE

dication of the relative importance of these nutrients. However, intervention studies are needed to further address this issue.

A limitation of our study may be the use of a semi-quantitative food frequency questionnaire method for assessing nutrient intake; as such, this method can be of limited validity or accuracy. However, our method was specially designed to measure calcium and vitamin D intake and has been shown to be of good validity and accuracy for most major nutrients, including calcium and vitamin D, compared with repeated 24-hour recalls or by associating serum 25-hydroxyvitamin D with vitamin D intake during winter (r = 0.7).11-13

Another limitation of our study is our single fasting measurement of serum PTH, which does not give an accurate portrayal of the calcium economy. Although a 24-hour integrated serum PTH would certainly be a better measure and manifesting the full effect of absorptive calcemia, such an effort is not feasible in a large study population. Similarly, our determination of serum 25-hydroxyvitamin D relied on a single measurement. In our study, serum PTH values seemed to level off at a serum 25-hydroxyvitamin D level of approximately 18 ng/mL, irrespective of calcium intake, and no statistically significant decrease was observed with increased serum 25-hydroxyvitamin D levels (>18 ng/mL). Different authors have reported different serum 25-hydroxyvitamin D levels for the inflection point of serum PTH and in some studies levels of more than 18 ng/mL are reported to be within the region of the curve.6-8,16 It has even been reported that no such value may exist.17 It is quite possible that serum PTH levels continue to decrease in response to serum 25-hydroxyvitamin D levels of more than 18 ng/mL; however, this was not evident from our study. Indeed, our study indicated that this curve may be dependent on calcium intake, which in turn may explain the differences observed between studies.

Although our data are based on a healthy subsample of the original random sample of the population, all analyses were also performed on the total group of participants, including those individuals with diseases or taking medications that affected calcium metabolism. Similar results were obtained from that larger group in all respects, demonstrating that a possibly distorted study group did not contribute to our results.

Our results are supported by the study of Kinyamu et al,18 which showed that serum PTH concentration is inversely associated with calcium intake derived from vitamin D–fortified milk, but not calcium from other sources. It has also been postulated that high calcium intake may have a vitamin D–sparing effect, possibly through suppressed serum PTH and decreased 1,25-dihydroxyvitamin D. Similarly a low calcium intake has been proposed to aggravate vitamin D deficiency through increased catabolism of 25-hydroxyvitamin D.19,20 The inverse hypothesis, however, that sufficient vitamin D may have a calcium-sparing effect has not to our knowledge been addressed previously.

Although the importance of preventing undue increases in serum PTH for bone health is generally recognized, evidence is lacking for identifying the exact levels that may be detrimental. However, secondary hyperparathyroidism is considered to play a significant role in the pathogenesis of age-related bone loss.21,22 Also, it is well recognized that serum PTH is the principal systemic determinant of bone remodelling, which itself is a risk factor for fractures irrespective of bone balance.23 Although sufficient intake of both nutrients is certainly important, our study indicates that as long as vitamin D status is secured by vitamin D supplements or sufficient sunshine, calcium intake levels of more than 800 mg/d may be unnecessary for maintaining calcium metabolism. Vitamin D supplements are necessary to ensure adequate vitamin D status for most of the year in northern climates.

Author Contributions: Drs Steingrimsdottir, Indridason, and Sigurdsson had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Indridason, Franzson, Sigurdsson.

Acquisition of data: Steingrimsdottir, Gunnarsson, Franzson.

Analysis and interpretation of data: Steingrimsdottir, Gunnarsson, Indridason, Franzson, Sigurdsson.

Drafting of the manuscript: Steingrimsdottir.

Critical revision of the manuscript for important intellectual content: Steingrimsdottir, Gunnarsson, Indridason, Franzson, Sigurdsson.

Statistical analysis: Gunnarsson, Indridason.

Obtained funding: Franzson, Sigurdsson.

Administrative, technical, or material support: Steingrimsdottir, Franzson, Sigurdsson.

Study supervision: Steingrimsdottir, Indridason, Franzson, Sigurdsson.

2340 JAMA, November 9, 2005—Vol 294, No. 18 (Reprinted) ©2005 American Medical Association. All rights reserved.
**Financial Disclosures:** None reported.

**Funding/Support:** This study was supported by a grant from the Science Fund of St. Joseph’s Hospital, Landakot, and the University Hospital, Reykjavik, Iceland.

**Role of the Sponsors:** The funding sources did not participate in the design and conduct of the study, in the collection, analysis, and interpretation of the data, or in the preparation, review, or approval of the manuscript.

**Acknowledgment:** We thank the dedicated and talented staff of Clinical Chemistry, Landspitali-University Hospital, Reykjavik, Iceland. We are indebted to all the participants of this population-based study.

**REFERENCES**